Touchstone
Last syncNov 1, 2026, 6:55 PM ET

OBX

Obsidian Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$14.79Close $206.2MMarket cap $11.77 – $35.0052-week range

Highlights

Strengths

  • Volume drying up last 10 days 35% under the 50-day average

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 28, 2026
Off 12-month high 58%
1wk up 5.8% price change
1mo up 7.7% price change
12-month return down 15% total, dividends included
F-score — — Not assessed
Altman Z 9.09 Low risk
P/E — price / earnings
PEG — P/E / EPS growth
P/B — price / book
Earnings yield down 63.7% EBIT / enterprise value
Cheaper than — of the market · not assessed
Revenue growth — year on year
EPS growth — latest quarter
Sales growth — latest quarter
ROE — return on equity
Free cash margin — -$90.5M FCF
D/E — long-term debt / equity
Net debt / EBITDA —
Interest cover —EBIT / interest

Trade setup

ATR% 9.4% $1.38 a day · 2×ATR $12.02
RS — vs the universe
Trend — trend template
Relative volume 1.2× vs 50-day average
Up/down volume 1.19 50 sessions
Implied move — no scheduled report
Contractions 2 71% → 42%
Pivot $19.97 25.9% below
Volume dry-up 0.7× 10 vs 50 sessions

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged
  • Liabilities exceed assets Shareholders' equity is negative at -$266.0M as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
Last reported Aug 3, 2026
Results reaction Aug 3, 2026+114% vs market2 sessions after results

Financials

2 fiscal years · from filings
Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $0
$0 $1 FY24 FY25 FY2024 · $0 FY2025 · $0
Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$100.6M
-$200M $0 FY24 FY25 FY2024 · -$83.1M FY2025 · -$100.6M
Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$90.5M
-$100M $0 FY24 FY25 FY2024 · -$75.8M FY2025 · -$90.5M
Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology
  • Cash
  • Long-term debt
$0 $50M FY24 FY25 FY2024 · Cash $49.8M FY2025 · Cash $40.4M
Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 13.94m +0.1% since FY2024
13.94m 13.92m FY24 FY25 FY2024 · 13.92m FY2025 · 13.94m
  FY2024Dec 31, 2024 FY2025Dec 31, 2025
Revenue $0 $0
Operating income -$91.3M -$105.7M
Net income -$83.1M -$100.6M
Earnings per share -$6.47 -$7.22
Free cash flow -$75.8M -$90.5M
Cash $49.8M $40.4M
Shareholders' equity -$174.4M -$266.0M
Shares outstanding 13.92m 13.94m